Trademark: 97412748
Word
APDUCE
Status
Registered
Status Code
700
Status Date
Tuesday, September 26, 2023
Serial Number
97412748
Registration Number
7172959
Registration Date
Tuesday, September 26, 2023
Mark Type
4000
Filing Date
Monday, May 16, 2022
Published for Opposition
Tuesday, July 11, 2023

Trademark Owner History
ASCENTAGE PHARMA (SUZHOU) CO., LTD. - Original Registrant

Classifications
5 Chemical preparations for medical purposes, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs sold in bulk, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biochemical medicines for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicines for human purposes for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compounds, next-generation kinase inhibitors and senolytic drugs; biological preparations for medical purposes, namely, biological preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical preparations for pharmaceutical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; radioactive substances for medical purposes; gases for medical purposes, namely, nitric oxide for medical purposes; chemical conductors for electrocardiograph electrodes; semen for artificial insemination; disinfectants; solutions for contact lenses; media for bacteriological cultures; medicated sweets; dietetic preparations adapted for medical use; depuratives for the body; diagnostic preparations for veterinary purposes; pesticides; sanitary napkins; cotton for medical purposes; dental abrasives; diapers for pets

Trademark Events
Sep 26, 2023
Notice Of Registration Confirmation Emailed
Sep 26, 2023
Registered-Principal Register
Jul 11, 2023
Official Gazette Publication Confirmation E-Mailed
Jul 11, 2023
Published For Opposition
Jun 21, 2023
Notification Of Notice Of Publication E-Mailed
Jun 5, 2023
Law Office Publication Review Completed
May 27, 2023
Approved For Pub - Principal Register
May 27, 2023
Examiner's Amendment Entered
May 27, 2023
Notification Of Examiners Amendment E-Mailed
May 27, 2023
Examiners Amendment E-Mailed
May 27, 2023
Examiners Amendment -Written
Apr 24, 2023
Teas/Email Correspondence Entered
Apr 24, 2023
Correspondence Received In Law Office
Apr 24, 2023
Teas Response To Office Action Received
Mar 12, 2023
Notification Of Non-Final Action E-Mailed
Mar 12, 2023
Non-Final Action E-Mailed
Mar 12, 2023
Non-Final Action Written
Mar 3, 2023
Assigned To Examiner
Jun 27, 2022
Preliminary/Voluntary Amendment - Entered
Jun 27, 2022
Assigned To Lie
Jun 14, 2022
Teas Voluntary Amendment Received
May 23, 2022
New Application Office Supplied Data Entered
May 19, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24